Accessibility Menu
 
Zynerba Pharmaceuticals logo

Zynerba Pharmaceuticals

(NASDAQ) ZYNE

Current PriceN/A
Market CapN/A
Since IPO (2015)-92%
5 Year-82%
1 Year+86%
1 Month-2%

Zynerba Pharmaceuticals Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

$37.01M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

ZYNE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zynerba Pharmaceuticals

Industry

Pharmaceuticals

Employees

27

CEO

Armando Anido, MBA

Headquarters

Devon, PA 19333, US

ZYNE Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-59%

Return on Capital

-76%

Return on Assets

-63%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Short Interest

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

$35.25M

EBITDA

$34.62M

Operating Cash Flow

$23.03M

Capital Expenditure

$154.10K

Free Cash Flow

$23.18M

Cash & ST Invst.

$50.64M

Total Debt

$334.43K

Zynerba Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

N/A

Market Cap/Employee

N/A

N/A

Employees

25

N/A

Net Income

$10.78M

-2.3%

EBITDA

$11.07M

-20.7%

Quarterly Fundamentals

Name
Q2 2023YOY CHG

Net Cash

$35.75M

-42.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$217.88K

+2.8%

Return on Assets

-62.72%

N/A

Return on Invested Capital

-76.06%

N/A

Free Cash Flow

$8.43M

-6.9%

Operating Cash Flow

$8.42M

-6.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VLNSThe Valens Company Inc.
$0.76+0.00%
LIENChicago Atlantic BDC, Inc.
$9.31-2.00%
QNCXQuince Therapeutics, Inc.
$0.10+15.64%
DRRXDURECT Corporation
$1.91-1.04%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.52+0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$37.89-0.02%
INTCIntel
$41.19-0.04%
ONDSOndas
$8.15-0.07%

Questions About ZYNE

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.